Enpro Inc Dossier
Qualitative Analysis
Business overview
Enpro Inc. (formerly EnPro Industries, Inc.) is a leading industrial technology company that designs and manufactures highly engineered products and materials for technology-intensive sectors globally. The company operates primarily through two core segments: Sealing Technologies (comprising Garlock, STEMCO, and Technetics divisions) and Advanced Surface Technologies (AST, which includes NxEdge, Technetics Semi, LeanTeq, and Alluxa). Enpro serves critical, high-barrier end markets including semiconductors, aerospace, power generation, heavy-duty trucking, and life sciences. Under its multi-year 'Enpro 3.0' strategy, the company has transformed its portfolio from a cyclical, capital-intensive industrial manufacturer into a high-margin, proprietary technology-focused compounder with significant aftermarket and recurring revenue streams.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A multi-year strategic roadmap focused on accelerating personal and profitable growth, shifting the portfolio toward high-margin, low-capital-intensity industrial technology businesses with recurring aftermarket revenue.
Expected impact: Targeting organic profitable growth, mid-to-high single-digit organic growth, strong free cash flow conversion near 100% of adjusted net income, and EBITDA margins exceeding 25%.
Expanding global infrastructure and capacity to support leading-edge precision cleaning solutions and semiconductor capital equipment demand.
Expected impact: Positioning Enpro on the leading edge of advanced node chip production and semiconductor supply chains, driving high-margin segment growth.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Broadens Enpro's position in compositional analysis by adding liquid analytical sensing technologies and instrumentation for liquid processes.
Financial impact: Combined with Overlook, expected to contribute over $60 million in annualized revenue and $17 million to $18 million in adjusted segment EBITDA.
Strengthens capabilities within the biopharma production value chain by adding proprietary single-use technologies and components for biopharmaceutical manufacturing.
Financial impact: Combined with AlpHa, expected to contribute over $60 million in annualized revenue and $17 million to $18 million in adjusted segment EBITDA.